
Assessing breast MRI scans, pathology and clinical data, the AI-powered TumorSight Risk software reportedly provides five- and 10-year risk for breast cancer recurrence for women with HR+, HER2-negative stage I-IIIA breast cancer.
The road to profit goes through a tiny burg called accuracy, which is sometimes harder to find than it should be. Vendors on the HIMSS09 exhibit floor offered their own kinds of medical GPS, some using off-the-shelf technologies spun up with a proprietary brand of software, others offering home brewed data handling techniques.
The road to profit goes through a tiny burg called accuracy, which is sometimes harder to find than it should be. Vendors on the HIMSS09 exhibit floor offered their own kinds of medical GPS, some using off-the-shelf technologies spun up with a proprietary brand of software, others offering home brewed data handling techniques.






